lunes, 19 de marzo de 2012

Monkeys And Medication: The Keys To MS Cure? | Medical News and Health Information

first step:
Monkeys And Medication: The Keys To MS Cure? | Medical News and Health Information

Monkeys And Medication: The Keys To MS Cure? -- Research Summary


BACKGROUND: Multiple sclerosis (MS) is an autoimmune disease that affects the brain and spinal cord (central nervous system). More than 400,000 Americans are suffer from MS. The disease is caused by damage to the protective covering that surrounds nerve cells, called the myelin sheath. When these nerve cells are damaged it causes nerve signals to slow down or stop completely. The nerve damage is usually caused by inflammation that occurs when the body's own immune cells attack the nervous system occurring in any area of the spinal cord, brain, and optic nerve. So far the cause of this disease is unknown, but commonly it is thought to happen because of either a virus or gene defect. People who have a family history of MS or live in an area where MS is more common might be more likely to develop this disease.

 
SYMPTOMS: As with many diseases, symptoms vary due to the severity of each attack. Episodes may last days, weeks, or months and are usually followed with a remission. Because nerves in any part of the brain or spinal cord may be damaged, patients with multiple sclerosis can have symptoms in many parts of the body.
1. Muscle symptoms: tremor in one or more arms or legs, weakness in one or more arms or legs, problems walking, problems moving arms or legs, numbness or abnormal sensation in any area, muscle spasms, loss of balance, and problems with coordination and making small movements.
2. Bowel and bladder symptoms: constipation and stool leakage, urine leakage, strong urge to urinate, frequent need to urinate, and difficulty beginning to urinate.
3. Eye symptoms: double vision, vision loss (usually only one eye at a time), eye discomfort, uncontrollable rapid eye movements.
4. Numbness, tingling, or pain: Painful muscle spasms, facial pain, tingling, crawling, or burning feeling in the arms and legs.
5. Other brain and nerve symptoms: Decreased attention span, poor judgment, and memory loss; depression or feelings of sadness, hearing loss, and dizziness (Source: www.ncbi.nlm.nih.gov)

 
NEW RESEARCH: So far there is not a known cure for MS. There are available medications and therapies to control symptoms, but the most recent discovery was found by the Oregon National Primate Research Center. They found that a natural disease in Japanese macaque monkeys (called Japanese macaque encephalomyelitis) is very similar to multiple sclerosis in humans. From 1986 through 2010, 56 monkeys at the research center developed paralysis in their legs and had to be euthanized. Later the researchers performed MRI scans on eight of them and they found that the MS-like disease caused the paralysis. The disease in the monkeys is very similar to a herpes virus. Researchers believe that a type of herpes virus could actually trigger MS in patients who have the disease in there genetics. Understanding how the herpes virus causes the disease similar to MS will give new important knowledge to developing more effective treatments for the disease or new methods to prevent the disease (Source: www.ohsu.edu).


OCRELIZUMAB: One characteristic of MS is inflammation, which takes the form of brain lesions. Ocrelizumab is a new antibody drug that has been proven to reduce the amount of brain lesions in MS patients. The drug successfully targets B cells, immune cells implicated in multiple sclerosis. B cells are now believed to drive the abnormal immune response in MS patients. An international multi-center study (79 centers in 20 countries) was conducted on 218 patients aged 18-55 years with relapsing-remitting multiple sclerosis and were split into 4 different groups. One group of 54 patients received placebo. The second and third groups of 54 received low and high doses of ocrelizumab. The fourth received the standard once-weekly treatment of intramuscular interferon beta-1a. After 24 weeks researchers found the number of active lesions was 89 percent lower in the ocrelizumab low-dose group and 96 percent lower in the high-dose group compared with the placebo group. The study showed that the drug rapidly reduced brain lesions in MS patients and could lead to fewer relapse. MORE


FOR MORE INFORMATION, PLEASE CONTACT:
Jim Newman
OHSU Strategic Communications
(503) 494-8231

third step:
Monkeys And Medication: The Keys To MS Cure? | Medical News and Health Information

No hay comentarios:

Publicar un comentario